Anti-AKT3 antibody

• IHC-P

Unknown

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-AKT3 antibody (AB152157)

Immunohistochemical analysis of paraffin-embedded A549 xenograft tissue, staining AKT3 using ab152157 at a 1/500 dilution.

• ICC/IF

Supplier Data

Immunocytochemistry/ Immunofluorescence - Anti-AKT3 antibody (AB152157)

Immunofluorescent analysis of methanol fixed MCF-7 cells labeling AKT3 with ab152157 at 1 in 500 dilution.

Blue : Hoechst 33342 staining.

• WB

Unknown

Western blot - Anti-AKT3 antibody (AB152157)

10% SDS PAGE

All lanes:

Western blot - Anti-AKT3 antibody (ab152157) at 1/1000 dilution

All lanes:

Raji whole cell lysate at 30 µg

Predicted band size: 56 kDa

false

• WB

Supplier Data

Western blot - Anti-AKT3 antibody (AB152157)

All lanes:

Western blot - Anti-AKT3 antibody (ab152157) at 1/1000 dilution

Lane 1:

Non-transfected 293T whole cell extracts at 30 µg

Lane 2:

Transfected (+) 293T whole cell extracts at 30 µg

Predicted band size: 56 kDa

false

• WB

Unknown

Western blot - Anti-AKT3 antibody (AB152157)

7.5% SDS PAGE

All lanes:

Western blot - Anti-AKT3 antibody (ab152157) at 1/1000 dilution

All lanes:

Mouse brain whole cell lysate at 50 µg

Predicted band size: 56 kDa

false

• WB

CiteAb

Western blot - Anti-AKT3 antibody (AB152157)

AKT3 western blot using anti-AKT3 antibody ab152157. Publication image and figure legend from Teng, Y., Zhang, Y., et al., 2015, Oncotarget, PubMed 26512921.

ab152157 was used in this publication in western blot. This may not be the same as the application(s) guaranteed by Abcam. For a full list of applications guaranteed by Abcam for ab152157 please see the product overview.

miR-29b directly targets and thus negatively regulates AKT2 and AKT3A. A schematic shows the prediction and screening process of miR-29b downstream target gene involved in cancerous glycolysis regulation by a series of microRNA bioinformatics softwares; B. Expression analysis between miR-29b and predicted downstream target genes using the NCI-60 expression profiling data. Among the five selected genes, AKT2 and AKT3 showed a significantly negative correlation against miR-29b level; C. qPCR results indicate that miR-29b inhibition increased AKT2 and AKT3 levels in A2780 cells, and miR-29b overexpression decreased AKT2 and AKT3 levels in SKOV3 cells. While no change in AKT1 levels was observed in both conditions; D. Western blot results show that miR-29b inhibition increased AKT2 and AKT3 levels, and miR-29b overexpression decreased AKT2 and AKT3 levels in both A2780 and SKOV3 cells. While no change in AKT1 levels was observed in both conditions; E. Schematic representation of different AKT2/AKT3 3'UTR luciferase reporters used in the transfection experiments are depicted; F. SKOV3/A2780 cells were co-transfected with either miR-29b or control mimics and 200 ng pGL3 reporter construct containing wild type or miR-29b site mutated 3'UTR of AKT2/3. The relative firefly luciferase activities normalized with renilla luciferase were measured 48 hours post-transfection and results are plotted as percentage change over respective controls. G. Immunohistochemical results reveal that expression of AKT2 and AKT3 is higher in EOC epithelia than in normal ovarian epithelia; H. Immunohistochemical results indicate a negative correlation between miR-29b and AKT2/3 levels in EOC epithelia. All IHC images were photographed under 400× magnification. Data are presented as means ± SEM, n = 3. *p < 0.05 versus control.

false